Gedda G, Park Y, Pang M
Obstet Gynecol Sci. 2024; 68(1):18-29.
PMID: 39591955
PMC: 11788694.
DOI: 10.5468/ogs.24180.
Braun G, Schaier M, Werner P, Theiner S, Zanghellini J, Wisgrill L
JACS Au. 2024; 4(6):2197-2210.
PMID: 38938797
PMC: 11200229.
DOI: 10.1021/jacsau.4c00154.
Sun T, Zhang P, Zhang Q, Wang B, Zhao Q, Liu F
Heliyon. 2024; 10(10):e30780.
PMID: 38765024
PMC: 11096979.
DOI: 10.1016/j.heliyon.2024.e30780.
Carmi Y, Khamaisi H, Adawi R, Noyman E, Gopas J, Mahajna J
Int J Mol Sci. 2023; 24(9).
PMID: 37175439
PMC: 10178190.
DOI: 10.3390/ijms24097730.
Khamaisi H, Mahmoud H, Mahajna J
Molecules. 2022; 27(3).
PMID: 35164068
PMC: 8839885.
DOI: 10.3390/molecules27030804.
Towards Imaging Pt Chemoresistance Using Gd(III)-Pt(II) Theranostic MR Contrast Agents.
Adams C, Meade T
ChemMedChem. 2021; 16(24):3663-3671.
PMID: 34355523
PMC: 8678168.
DOI: 10.1002/cmdc.202100389.
In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([Pt]cisplatin) Emitting Auger Electrons.
Obata H, Tsuji A, Sudo H, Sugyo A, Minegishi K, Nagatsu K
Int J Mol Sci. 2021; 22(9).
PMID: 33924843
PMC: 8124180.
DOI: 10.3390/ijms22094622.
Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Carmi Y, Mahmoud H, Khamaisi H, Adawi R, Gopas J, Mahajna J
Int J Mol Sci. 2020; 21(18).
PMID: 32906729
PMC: 7555577.
DOI: 10.3390/ijms21186533.
Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors.
De Giorgi U, Casadei C, Bergamini A, Attademo L, Cormio G, Lorusso D
Cancers (Basel). 2019; 11(10).
PMID: 31627378
PMC: 6826947.
DOI: 10.3390/cancers11101584.
Transformation of follicular lymphoma to double-hit lymphoma during adjuvant chemotherapy for concurrent ovarian carcinoma.
Narazaki T, Nakashima Y, Tsukamoto Y, Tsuda M, Masuda T, Kimura D
Int J Hematol. 2019; 110(3):375-380.
PMID: 31104212
DOI: 10.1007/s12185-019-02656-4.
Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells.
Lee S, Yu D, Lee D, Shin H, Jo J, Lee Y
Cancer Sci. 2018; 110(2):662-673.
PMID: 30485589
PMC: 6361556.
DOI: 10.1111/cas.13894.
Activated Integrated Stress Response Induced by Salubrinal Promotes Cisplatin Resistance in Human Gastric Cancer Cells via Enhanced xCT Expression and Glutathione Biosynthesis.
Wang S, Wung C, Chen M, Chen C, Yin P, Yeh T
Int J Mol Sci. 2018; 19(11).
PMID: 30380689
PMC: 6275069.
DOI: 10.3390/ijms19113389.
An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.
Ling X, Wu W, Fan C, Xu C, Liao J, Rich L
J Exp Clin Cancer Res. 2018; 37(1):240.
PMID: 30285798
PMC: 6169080.
DOI: 10.1186/s13046-018-0899-8.
PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Jiang Y, Dai H, Li Y, Yin J, Guo S, Lin S
Int J Cancer. 2018; 144(5):1092-1103.
PMID: 30152517
PMC: 6320711.
DOI: 10.1002/ijc.31770.
Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients.
Cao Y, Chang Q, Cabanero M, Zhang W, Hafezi-Bakhtiari S, Hedley D
J Gastrointest Cancer. 2018; 50(4):801-807.
PMID: 30117091
DOI: 10.1007/s12029-018-0153-9.
Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.
Lai Y, Kuo C, Kuo M, Chen H
Int J Mol Sci. 2018; 19(5).
PMID: 29772714
PMC: 5983780.
DOI: 10.3390/ijms19051486.
Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells.
Sun X, Wei Q, Cheng J, Bian Y, Tian C, Hu Y
Hum Cell. 2017; 30(3):216-225.
PMID: 28326487
PMC: 5486860.
DOI: 10.1007/s13577-017-0167-9.
Base-Resolution Analysis of Cisplatin-DNA Adducts at the Genome Scale.
Shu X, Xiong X, Song J, He C, Yi C
Angew Chem Int Ed Engl. 2016; 55(46):14246-14249.
PMID: 27736024
PMC: 5131569.
DOI: 10.1002/anie.201607380.
Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.
Dwivedi S, Mustafi S, Mangala L, Jiang D, Pradeep S, Rodriguez-Aguayo C
Oncotarget. 2016; 7(12):15093-104.
PMID: 26918603
PMC: 4924772.
DOI: 10.18632/oncotarget.7618.
Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J
BMC Cancer. 2016; 16:140.
PMID: 26906901
PMC: 4763415.
DOI: 10.1186/s12885-016-2182-8.